Research Tracker›Biomarker Atlas›Marker Pages›Asymmetric Dimethylarginine (ADMA)

Asymmetric Dimethylarginine (ADMA) across conditions

Asymmetric Dimethylarginine (ADMA) appears in 2 entries of the OSMF biomarker atlas, covering Hypertension, Long COVID. Across those entries it is elevated in 1, mixed in 1. Because the same marker shifts in several unrelated conditions, it is best understood as a signal of shared biology such as inflammation, vascular or metabolic stress rather than as a condition-specific test. Each row below links to a page with the comparison group, associated symptoms, test details and primary citation.

HypertensionLong COVID

Where Asymmetric Dimethylarginine (ADMA) is reported

Also listed as: Asymmetric dimethylarginine (ADMA); NO synthase inhibitor

ConditionDirectionCompared againstAssociated symptomsSource
Hypertension↕ inconsistentnormotension groupdisaster-related hypertension after Great East Japan EarthquakeShiraishi et al. 2016
Long COVID↑ elevatedhealthy controlsReduced NO bioavailabilityThomas et al. 2024

Frequently asked questions

In which conditions is Asymmetric Dimethylarginine (ADMA) altered?

In the OSMF atlas Asymmetric Dimethylarginine (ADMA) is reported in Hypertension, Long COVID. It is elevated in 1, mixed in 1 across 2 entries.

Does Asymmetric Dimethylarginine (ADMA) point to one specific diagnosis?

No. Because Asymmetric Dimethylarginine (ADMA) changes in several conditions (Hypertension, Long COVID), an abnormal result cannot identify which condition, if any, is present. It must be interpreted with symptoms, history and other tests.

What is the LOINC code for Asymmetric Dimethylarginine (ADMA)?

Entries in this atlas use LOINC 74363-3. LOINC codes identify the laboratory observation so results can be compared across systems.

Is one abnormal Asymmetric Dimethylarginine (ADMA) result diagnostic?

No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.

Cite this page

Open Source Medicine Foundation. (2026). Asymmetric Dimethylarginine (ADMA) across conditions: biomarker evidence. OSMF Research Tracker. Retrieved November 21, 2026, from https://research.opensourcemed.info/biomarkers/markers/asymmetric-dimethylarginine-adma.html

Last reviewed: 2026-10-08 · Browse: Biomarker Index · All marker pages · Biomarker Atlas

Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.